<DOC>
	<DOCNO>NCT00203814</DOCNO>
	<brief_summary>The purpose study determine efficacy sulfadoxine-pyrimethamine plus artesunate versus sulfadoxine-pyrimethamine alone treatment uncomplicated malaria .</brief_summary>
	<brief_title>A Randomised Efficacy Study Combination Antimalarials Treat Uncomplicated Malaria</brief_title>
	<detailed_description>Resistance Plasmodium falciparum anti-malarial drug serious impediment control malaria . In order facilitate formulation effective regional drug policy provide database decision-making implementation combination therapy ( CAT ) , essential vivo response CAT investigate . In South East African Combination Anti-malarial Therapy ( SEACAT ) evaluation , comprehensive evaluation phase introduction combination anti-malarial therapy Mozambique . As component evaluation , select Mozambique sit intensity malaria transmission high , direct parallel group comparison monotherapy ( SP ) CAT ( artesunate plus SP ) conduct accord protocol .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>Male female , old 12 month . Weight &gt; 10 kg . Diagnoses pure uncomplicated acute P. falciparum malaria parasitaemia 500 000 asexual parasite/mcl blood axillary temperature great equal 37.5Â°C history fever ( define within previous 24 hour ) . Documented informed consent . Lives close enough study site reliable follow . Has receive antimalarial treatment past 7 day . Is infected malarial specie ( subject may exclude retrospectively analysis ) . Severely ill ( base WHO Criteria severe malaria ) patient consider , opinion investigator designee , moderately severe malaria ( e.g . prostrate , repeat vomiting , dehydrate ) danger sign . Has receive cotrimoxazole , trimethoprim , chloramphenicol , folate tetracycline ( include doxycycline ) past 7 day likely require study period . History G6PD deficiency . Is pregnant breastfeeding . Has history allergy study drug ( include sulphonamides e.g . cotrimoxazole , artemisinin derivative e.g . coartemether ) . Serious underlying disease opinion clinic team and/or Principal Investigator would make patient unsuitable study term safety study analysis .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Gametocyte</keyword>
	<keyword>Molecular marker</keyword>
	<keyword>Sulfadoxine-pyrimethamine</keyword>
	<keyword>Artesunate</keyword>
	<keyword>Artemisinin</keyword>
</DOC>